down arrow

Inovio Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45773H2013
USD
2.02
0.1 (5.21%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.972.06

52 Week

1.304.44
Valuation
Technical
Day's Volume

CASH

101.68 k

Shareholding (Mar 2025)

FII

2.79%

Held by 47 FIIs

DII

81.73%

Held by 17 DIIs

Promoter

0.21%

How big is Inovio Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Inovio Pharmaceuticals, Inc. has a market capitalization of 69.68 million, with net sales of 0.29 million and a net profit of -96.48 million over the latest four quarters. Shareholder's funds are reported at 68.50 million, and total assets amount to 114.90 million.

As of Jun 18, Inovio Pharmaceuticals, Inc. has a market capitalization of 69.68 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.29 million, while the sum of net profit for the same period is -96.48 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 68.50 million, and total assets amount to 114.90 million.

Read More

What does Inovio Pharmaceuticals, Inc. do?

22-Jun-2025

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing DNA immunotherapies and vaccines for cancer and infectious diseases. As of March 2025, it has a market cap of $69.68 million, with net sales of $0 and a net loss of $20 million.

Overview: <BR>Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company focused on developing DNA immunotherapies and vaccines for treating and preventing cancers and infectious diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -20 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 69.68 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.28 <BR>Return on Equity: -204.32% <BR>Price to Book: 1.36<BR><BR>Contact Details: <BR>Address: 6769 Mesa Ridge Rd, SAN DIEGO CA: 92121-2995 <BR>Tel: 1 858 4103134 <BR>Fax: 1 858 4041392 <BR>Website: http://www.inovio.com/

Read More

Who are in the management team of Inovio Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Inovio Pharmaceuticals, Inc. includes Mr. Simon Benito (Independent Chairman), Dr. Jong Kim (CEO), Dr. David Weiner, Dr. Ann Miller, Mr. Jay Shepard, Ms. Wendy Yarno, and Ms. Lota Zoth (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Inovio Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Simon Benito, Independent Chairman of the Board<BR>- Dr. Jong Kim, President, Chief Executive Officer, and Director<BR>- Dr. David Weiner, Director<BR>- Dr. Ann Miller, Independent Director<BR>- Mr. Jay Shepard, Independent Director<BR>- Ms. Wendy Yarno, Independent Director<BR>- Ms. Lota Zoth, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Read More

Is Inovio Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of November 9, 2023, Inovio Pharmaceuticals, Inc. is considered overvalued with a valuation grade change to "does not qualify," marked by a Price to Book Value of 1.62, negative EV to EBIT and EV to EBITDA ratios, and a Return on Equity of -204.32%, alongside a troubling long-term performance decline of 99.25% over five years.

As of 9 November 2023, Inovio Pharmaceuticals, Inc. has seen its valuation grade change from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued, as reflected by its Price to Book Value of 1.62 and negative ratios such as EV to EBIT at -0.16 and EV to EBITDA at -0.17. Additionally, the Return on Equity (ROE) stands at a staggering -204.32%, highlighting severe inefficiencies and losses.<BR><BR>When compared to peers, Inovio's valuation metrics are concerning. For instance, Mind Medicine (MindMed), Inc. and Talaris Therapeutics, Inc. also do not qualify, with EV to EBITDA ratios of -2.78 and -2.21, respectively, indicating similar struggles within the sector. Despite a year-to-date return of 5.46%, which is better than the S&P 500's 2.44%, the long-term performance is alarming, with a 1-year decline of 76.14% and a staggering 99.25% drop over the past five years. This further reinforces the conclusion that Inovio Pharmaceuticals is currently overvalued.

Read More

Is Inovio Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Inovio Pharmaceuticals' technical trend is neutral with mixed indicators, showing a shift from mildly bullish to sideways, and it has significantly underperformed the S&P 500 with returns of -65.88% over the past year and -90.03% over three years.

As of 12 September 2025, the technical trend for Inovio Pharmaceuticals, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed indicators. The weekly MACD and Dow Theory are mildly bullish, while the daily moving averages are mildly bearish. The monthly RSI shows bullish momentum, but Bollinger Bands indicate a bearish trend. In terms of returns, the stock has underperformed the S&P 500 over the past year and three years, with a -65.88% return compared to the S&P 500's 17.14%, and a staggering -90.03% over three years versus the S&P 500's 70.41%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 153 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.57

stock-summary
Return on Equity

-332.63%

stock-summary
Price to Book

5.35

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-24 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-25.46%
0%
-25.46%
6 Months
-4.72%
0%
-4.72%
1 Year
-51.9%
0%
-51.9%
2 Years
-57.71%
0%
-57.71%
3 Years
-91.5%
0%
-91.5%
4 Years
-97.27%
0%
-97.27%
5 Years
-98.66%
0%
-98.66%

Inovio Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Inovio Pharmaceuticals, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Inovio Pharmaceuticals, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed indicators. The weekly MACD and Dow Theory are mildly bullish, while the daily moving averages are mildly bearish. The monthly RSI shows bullish momentum, but Bollinger Bands indicate a bearish trend. In terms of returns, the stock has underperformed the S&P 500 over the past year and three years, with a -65.88% return compared to the S&P 500's 17.14%, and a staggering -90.03% over three years versus the S&P 500's 70.41%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-41.99%
EBIT Growth (5y)
2.53%
EBIT to Interest (avg)
-110.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.28
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
45.81%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.62
EV to EBIT
-0.16
EV to EBITDA
-0.17
EV to Capital Employed
-1.20
EV to Sales
17.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-204.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 23 Schemes (15.27%)

Foreign Institutions

Held by 47 Foreign Institutions (2.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -19.29% vs -1.55% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.30",
          "val2": "-24.30",
          "chgp": "8.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.10",
          "val2": "3.90",
          "chgp": "-128.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.50",
          "val2": "-19.70",
          "chgp": "-19.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-383,369.70%",
          "chgp": "38,336.97%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -75.00% vs -92.23% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 20.58% vs 51.72% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.80",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-110.90",
          "val2": "-131.70",
          "chgp": "15.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "1.20",
          "chgp": "-83.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "4.90",
          "val2": "-4.70",
          "chgp": "204.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-107.30",
          "val2": "-135.10",
          "chgp": "20.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-523,516.80%",
          "val2": "-162,530.10%",
          "chgp": "-36,098.67%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-22.30
-24.30
8.23%
Interest
0.00
0.00
Exceptional Items
-1.10
3.90
-128.21%
Consolidate Net Profit
-23.50
-19.70
-19.29%
Operating Profit Margin (Excl OI)
0.00%
-383,369.70%
38,336.97%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -19.29% vs -1.55% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.20
0.80
-75.00%
Operating Profit (PBDIT) excl Other Income
-110.90
-131.70
15.79%
Interest
0.20
1.20
-83.33%
Exceptional Items
4.90
-4.70
204.26%
Consolidate Net Profit
-107.30
-135.10
20.58%
Operating Profit Margin (Excl OI)
-523,516.80%
-162,530.10%
-36,098.67%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -75.00% vs -92.23% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 20.58% vs 51.72% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Inovio Pharmaceuticals, Inc. stock-summary
stock-summary
Inovio Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Company Coordinates stock-summary
Company Details
6769 Mesa Ridge Rd , SAN DIEGO CA : 92121-2995
stock-summary
Tel: 1 858 4103134
stock-summary
http://www.inovio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."